Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.

Bagsværd, Denmark, 17 January 2025 – Novo Nordisk today announced headline results from STEP UP, a phase 3b trial in the ...

In an important regulatory win for Denmark’s Novo Nordisk, the US Food and Drug Administration (FDA) yesterday approved ...

Now that Novo Nordisk is the world’s weight-loss juggernaut, will it have to betray its first patients—type 1 diabetics?

President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish territory, "for national security purposes." But Greenland Prime Minister ...

In recent years, the pharmaceutical industry has undergone significant changes in the focus of its innovation, research and ...

HealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...

President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland could disrupt one export that is wildly popular in America: Ozempic.

A safety committee will review all evidence from trials and studies to shed more light on the potential risk of NAION.

Two large studies from the University of Southern Denmark suggest that the diabetes ... among users of semaglutide than among users of other antidiabetic medications. This finding is very ...

Semaglutide, sold under the brand names of Ozempic, Rybelsus and Wegovy, is one of the most popular drugs on the market.

Jakob Grauslund, DMSci, PhD, MD, from Odense University Hospital in Denmark, and colleagues prospectively evaluated the use of semaglutide and risk for NAION in people with type 2 diabetes.